

**FDA APPROVES FIRST AND ONLY AUTOINJECTOR
FOR PSORIATIC AND RHEUMATIC DISEASES**

-- Approval of ENBREL SureClick™ Autoinjector Provides a New Administration Option for Patients With Hand Discomfort or Who May Have Resisted a Biologic Injectable --

WHAT: The FDA has approved the Enbrel® (etanercept) SureClick™ autoinjector, the first and only autoinjector for psoriatic and rheumatic diseases. Patients with rheumatoid arthritis and psoriatic arthritis can have hand discomfort, which can make it difficult to administer an injection. The ENBREL SureClick™ autoinjector is a new option for these patients. The ENBREL SureClick™ autoinjector also provides a new administration option for rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis patients who may have resisted a biologic injectable due to a fear of needles.

ENBREL is approved to treat five conditions: moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe rheumatoid arthritis, moderate to severe juvenile rheumatoid arthritis and ankylosing spondylitis.

With the approval of the ENBREL SureClick™ autoinjector, ENBREL is now available in three administration options including the 50 mg/mL prefilled syringe, 25 mg multiple use vial and ENBREL SureClick™ autoinjector. This suite of administration options enables patients to work with their rheumatologists or dermatologists to select an option that can meet their individual needs.

The ENBREL SureClick™ autoinjector is expected to be available to patients this summer.

About ENBREL SureClick™ Autoinjector:

- The simple, secure single-use autoinjector comes prefilled with a 50 mg/mL dose of ENBREL.
- ENBREL SureClick™ autoinjector also provides patients with three safety features
 - A safety needle cover that unlocks when the autoinjector is placed firmly against the injection site.
 - Two audible “clicks” to announce the beginning and end of the injection.
 - A large inspection window to let patients see if they have received their dose.
- With ENBREL SureClick™ autoinjector, patients never see the needle.
- The Arthritis Foundation has awarded ENBREL SureClick™ autoinjector its Ease-of-Use Commendation.

WHY: Amgen and Wyeth Pharmaceuticals are committed to improving the lives of patients with chronic diseases including psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis and juvenile rheumatoid arthritis.

VISUAL: A high-resolution ENBREL SureClick™ autoinjector photo is available.

FACTS ABOUT ENBREL:

- ENBREL has more than 13 years of collective clinical experience. ENBREL has been used by more than 400,000 patients worldwide across indications.
- For important product information please visit www.enbrel.com.

CONTACT: Nurha Hindi, Amgen
nhindi@amgen.com or 805-447-7331

ENBREL Indications:

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderate to severe active rheumatoid arthritis. ENBREL can be taken in combination with methotrexate or used alone.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one more DMARDs.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Important Product Information:

All medicines have side effects, including ENBREL. Possible side effects of ENBREL include:

- Serious infections
 - **Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes**
 - **Some serious infections have been fatal**
 - **Rare cases of tuberculosis have occurred**

What not to do

 - **Do not start ENBREL if you have an infection, such as an open sore or the flu, or are allergic to ENBREL or its components**

What to do

 - **Tell your doctor if you are prone to infection**
 - **Stop ENBREL if a serious infection occurs**
 - **Contact your doctor if you have questions about ENBREL or develop an infection**
 - **Tell your doctor if you have ever been treated for heart failure**
- Serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes
 - Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL
- Rare reports of serious blood disorders (some fatal)
 - Contact your doctor immediately if you develop symptoms, such as persistent fever, bruising, bleeding, or paleness
- In medical studies of all TNF blockers, including ENBREL, a higher rate of lymphoma (a type of cancer) was seen compared to the general population. The risk of lymphoma may be up to several-fold higher in rheumatoid arthritis and psoriasis patients
 - The role of TNF blockers, including ENBREL, in the development of lymphoma is unknown
- ENBREL can cause injection site reactions

###